Amsa: A phase II trial in resistant and recurrent acute myelogenous leukemia

1 January 1984

journal article
research article
Published by Wiley in Medical and Pediatric Oncology

Vol. 12 (3) , 178-179
https://doi.org/10.1002/mpo.2950120307

Abstract

27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA. Three achieved a complete remission, and two a partial remission. Median survival for all patients was 12 weeks and was 16 weeks for responders.

Keywords

This publication has 12 references indexed in Scilit:

Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults
Blood, 1982
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B
Blood, 1981
TREATMENT OF ACUTE MYELOCYTIC-LEUKEMIA - A STUDY BY CANCER AND LEUKEMIA GROUP-B
1981
4′-(9-Acridinylamino) Methanesulfon-m-Anisidide (AMSA): A New Drug Effective in the Treatment of Adult Acute Leukemia
Annals of Internal Medicine, 1980
Amsacrine (AMSA)
Cancer Treatment Reviews, 1980
PHASE-I AND PHASE-II TRIAL OF 4'-(9-ACRIDINYLAMINO)METHANESULFON-META-ANISIDIDE IN PATIENTS WITH ACUTE-LEUKEMIA
1980
HIGH REMISSION-INDUCTION RATE IN ACUTE MYELOID LEUKÆMIA
The Lancet, 1977
The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series
Published by Elsevier ,1974